Compare RVLV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | TRVI |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 2018 | 2019 |
| Metric | RVLV | TRVI |
|---|---|---|
| Price | $18.42 | $13.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $29.73 | $21.55 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.64 | ★ 31.91 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,225,682,000.00 | N/A |
| Revenue This Year | $10.96 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $91.55 | ★ N/A |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $17.35 | $5.38 |
| 52 Week High | $31.68 | $16.12 |
| Indicator | RVLV | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 41.92 |
| Support Level | $18.08 | $13.11 |
| Resistance Level | $22.53 | $13.55 |
| Average True Range (ATR) | 1.29 | 0.79 |
| MACD | -0.47 | -0.20 |
| Stochastic Oscillator | 11.02 | 3.17 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.